This educational activity is directed toward hematologists and other health care providers involved in the management of patients with hemophilia A and B.
The mainstay of therapy in hemophilia is supplementation of the missing factor VIII or factor IX proteins. The relatively short plasma half-life of these agents results in the need for frequent intravenous (IV) injections. Attempts have been made to engineer these factors to remain in the circulation longer and reduce the number of IV injections. Several improved therapeutic agents have recently arrived on the market, and hemophilia management is undergoing significant changes. Providing customized treatment based on each patient’s priorities and allowing the patient to design the treatment plan with the medical team can help maximize adherence. Pharmacokinetics and patients’ levels of physical activity should both inform an individualized prophylactic regimen that minimizes the risks of bleeds.
This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of hemophilia A and B, with a forward-looking perspective on how new agents might impact clinical practice. The essentials of current and emerging treatment strategies and clinical trial data for emerging treatments will be presented in a multimedia format, including a series of audio interviews with an expert thought leader that is integrated into text-based elements.